Preparation of an Antibiotic Crystalline Fusidic Acid

Total Page:16

File Type:pdf, Size:1020Kb

Preparation of an Antibiotic Crystalline Fusidic Acid (19) TZZ__T (11) EP 1 945 654 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07J 13/00 (2006.01) A61K 31/575 (2006.01) 19.08.2015 Bulletin 2015/34 A61P 31/00 (2006.01) (21) Application number: 06805540.9 (86) International application number: PCT/DK2006/000600 (22) Date of filing: 30.10.2006 (87) International publication number: WO 2007/051468 (10.05.2007 Gazette 2007/19) (54) PREPARATION OF AN ANTIBIOTIC CRYSTALLINE FUSIDIC ACID HERSTELLUNG EINER ANTIBIOTISCHEN KRISTALLINEN FUSIDINSÄURE PREPARATION D’UNE SUBSTANCE ANTIBIOTIQUE CRISTALLINE DE L’ ACIDE FUSIDIQUE (84) Designated Contracting States: • ANDERSEN, Niels, Rastrup AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2720 Vanløse (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (56) References cited: BE-A- 619 287 DE-A1- 1 468 178 (30) Priority: 31.10.2005 US 731247 P ES-A1- 2 204 331 ES-A1- 2 208 110 FR-A- 1 326 076 GB-A- 930 786 (43) Date of publication of application: RU-C2- 2 192 470 23.07.2008 Bulletin 2008/30 • HIKINO HIROSHI ET AL: "Fungal metabolites. II. (73) Proprietor: LEO PHARMA A/S Fusidic acid, a steroidal antibiotic from Isaria 2750 Ballerup (DK) kogane" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF (72) Inventors: JAPAN, TOKYO, JP, vol. 20, no. 5, 1972, pages • JENSEN, Jan 1067-1069, XP008080392 ISSN: 0009-2363 DK-2980 Kokkedal (DK) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 945 654 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 945 654 B1 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to a novel crystalline form of fusidic acid, to its preparation, pharmaceutical compositions containing it, and to the use of said crystalline fusidic acid form that can be used as a medicament in treatment of infectious diseases. BACKGROUND OF THE INVENTION 10 [0002] Fusidic acid [CAS6990-06-3] [Nature, Vol. 193, No. 4819, p. 987, 1962] which can be isolated from the fer- mentation broth of Fusidium coccineum is the most antibiotically active compound of the fusidanes and is the only fusidane used clinically in treatment of infectious diseases. Fusidic acid (Fucidin ®) is used clinically for the treatment of severe staphylococcal infections, particularly in bone and joint infections, in both the acute and the intractable form of 15 the disease (The Use of Antibiotics, 5th Ed., A. Kucers and N.McK. Bennett (Eds.), Butterworth 1997, pp. 580-587, and references cited therein). 20 25 30 35 [0003] Although fusidic acid is most commonly used against staphylococci, it is also used against several other gram- positive species. The clinical value of fusidic acid is also due to its efficient distribution in various tissues, low degree o f toxicity and allergic reactions and the absence cross-resistance with other clinically used antibiotics. Fusidic acid is widely used in local therapy for a number of skin and eye infections caused by staphylococci. It is generally given in combination with common antibiotics such as penicillins, erythromycins or clindamycin. It has also been used as an 40 alternative to vancomycin for the control of Gostridium difficile. Compared to staphylococci, several other gram-positive cocci are often less susceptible to fusidic acid. As an example, streptococcal species are generally up to 100-fold less sensitiveto fusidic acid thanstaphylococci [Kucherset al; supra]. Other sensitive bacteria include gram-positive anaerobic cocci, such as Peptococcus and Peptostreptococcus spp., aerobic or anaerobic gram-positive bacteria, such asCo- rynebacterium diphtheriae, Clostridium tetani, Clostridium difficile and Clostridium perfringens. Gram-negative bacteria 45 are resistant except for Neisseria spp. and Legionella pneumophila. The drug is highly potent against both intracellular and extracellular M. leprae. [0004] The solid form, such as the crystal form, of a drug substance or active pharmaceutical ingredient used in a pharmaceutical formulation or medicament is important based on solubility, dissolution rate, hygroscopicity, bioavaila- bility, and stability differences between the different solid forms. Thus the existence of various solid forms, such as 50 polymorphism or pseudo polymorphism can affect the properties of the quality of the drug product. [0005] Hence, a specific crystal form, including solvates and hydrates, might be preferable over another one. Further- more certain forms may be preferable depending on the specific formulation and/or application. For example, the prop- erties of a drug, such as the dissolution rate of the active ingredient, may be tuned by the proper choice of a certain crystal form, or mixtures thereof. 55 [0006] In a specific commercial pharmaceutical formulation, fusidic acid is presently marketed [see Monographs in the European Pharmacopeia 5.0] as a hemihydrate, which is the only hemihydrate form which has been described. [0007] Patent GB 930,786 discloses salts of fusidic acid with organic and inorganic bases, solvates of fusidic acid, namely a benzene solvate and a methanol solvate. This patent further discloses an unspecified fusidic acid form with 2 EP 1 945 654 B1 -1 22 IR absorption bands (KBr) at 1265, 1385, 1695, 1730 and 3450 cm and having a specific rotation [α]D of minus 9 degrees (1% solution in CHCl 3) obtainable by crystallisation of the methanol solvate of fusidic acid from ether. However, this form is distinct from the form of the present invention evident from the depicted IR spectrum in GB 930,786 which indicates that this form actually corresponds to the presently marketed hemihydrate form. 5 [0008] Solvates and salts of fusidic acid have also been disclosed in British patent GB 999,794. Patent ES 2208110 discloses two solvent free crystalline forms of fusidic acid called Form I and Form II, and a crystalline hemihydrate called Form III which is identical to the presently marketed hemihydrate, respectively. The crystalline forms were identified and characterised by IR spectroscopy, differential scanning calorimetry, X-ray diffraction and melting points. [0009] Patent WO 96/03128 discloses tablets containing a sodium salt form of fusidic acid and WO 86/03966 describes 10 an ophthalmic gel composition comprising an undefined form of suspended fusidic acid. SUMMARY OF THE INVENTION [0010] The present invention surprisingly provides a novel crystalline form of fusidic acid and a process for the prep- 15 aration of said crystalline fusidic acid. [0011] In one aspect, this invention relates to crystalline fusidic acid characterised by exhibiting one or more of the following features a)-f), respectively: a) a fourier transform (FT-NIR) Raman spectrum exhibiting one or more of the following intensity peaks at 3008, 20 2937, 2871, 172 5, 1707, 1666, 1651, 1468, 1379, 1348, 1195, 1078, 1032, 972, 917, 792, 745, 696, 612, 569, 547, 527, 463, 175, 120, or 86 (63 cm-1), respectively; b) an attenuated total reflectance fourier transform infrared (FTIR-ATR) spectrum exhibiting one or more of the following attenuated total reflectance peaks at 3644, 3489, 2992, 2937, 2871, 1722, 1708, 1442, 1381, 1352, 1283, 1255, 1218, 1204, 1175, 1149, 1109, 1069, 1048, 1028, 962, 941, 917, 851, 828, 791, 750, 690, or 656 ( 63 cm’ 1), 25 respectively; c) a near infrared (FT-NIR) spectrum exhibiting one or more of the following absorbance peaks at 10414, 8373, 7115, 6846, 6503, 5824, 4996; 4889, 4831, 4680, 4365, 4306, or 4067 ( 65 cm-1), respectively; d) an X-ray powder diffractogram (XRD) exhibiting one or more of the following angles of reflection 2 θ (60.1) at 7.2, 9.3, 9.9, 12.6, 13.1, 14.3, 14.7, 14.9, 15.4, 16.7, 17.9, 18.1, 18.5, 18.9, 19.5, 20.8, 21.8, 22.7, 23.5, 24.0, 24.4, 25.3, 30 26.0, 26.6, 26.8, 28.2, 28.9, or 29.7, respectively; e) a 13C CP/MAS solid-state NMR spectrum exhibiting one or more of the following resonances at 173.9, 169.3, 146.1, 137.0, 133.3, 120.6, 76.2, 71.1, 69.1, 49.7, 49.4, 45.0, 39.9, 38.5, 36.9, 35.8, 34.5, 32.7, 30.9, 29.5, 28.0, 26.5, 20.7, 20.0, 18.0, or 16.9 (60.5) ppm, respectively; or f) one or more of the following single-crystal X-ray diffraction experimental data: crystal system = monoclinic, space 35 group = P21, a [Å] = 12.2, b [A] = 8.0, c [A] = 13.9, α [°] = 90 β [°] = 94, γ [°] = 90, cell volume [Å3] = 1360, or Z = 2, respectively. [0012] In yet another aspect, this invention relates to isolated crystalline fusidic acid of the present invention as defined above which has a polymorphic purity of at least 80%, such as 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 40 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. [0013] In yet another aspect, this invention relates to isolated fusidic acid of the present invention as defined above which has a degree of crystallinity of at least 80%, such as %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. [0014] In yet another aspect, this invention relates to a mixture or composition of crystalline forms of fusidic acid, 45 including pseudopolymorphs of fusidic acid, comprising crystalline fusidic acid of the present invention as defined above.
Recommended publications
  • Early-Life Antibiotic Use and Risk of Asthma and Eczema: Results of a Discordant Twin Study
    Early View Original article Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study Elise M.A. Slob, Bronwyn K. Brew, Susanne J.H. Vijverberg, Chantal J.A.R. Kats, Cristina Longo, Mariëlle W. Pijnenburg, Toos C.E.M. van Beijsterveldt, Conor V. Dolan, Meike Bartels, Patrick Magnusson, Paul Lichtenstein, Tong Gong, Gerard H. Koppelman, Catarina Almqvist, Dorret I. Boomsma, Anke H. Maitland-van der Zee Please cite this article as: Slob EMA, Brew BK, Vijverberg SJH, et al. Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study. Eur Respir J 2020; in press (https://doi.org/10.1183/13993003.02021-2019). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2020 Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study Elise M.A. Slob1,2 Bronwyn K. Brew3,4 Susanne J.H. Vijverberg1,2 Chantal J.A.R. Kats1 Cristina Longo1 Mariëlle W. Pijnenburg5 Toos C.E.M. van Beijsterveldt6 Conor V. Dolan6 Meike Bartels6 Patrick Magnusson3 Paul Lichtenstein3 Tong Gong3 Gerard H. Koppelman7,8 Catarina Almqvist3,9 Dorret I. Boomsma6 Anke H. Maitland-van der Zee1,2* 1. Department of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, P.O.
    [Show full text]
  • Aminoglycosides for Intra-Abdominal Infection: Equal to the Challenge? John A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by VCU Scholars Compass Virginia Commonwealth University VCU Scholars Compass Publications from the Office of the Dean Office of the Dean 2004 Aminoglycosides for Intra-Abdominal Infection: Equal to the Challenge? John A. Bailey Saint Louis University Katherine S. Virgo Saint Louis University Joseph T. DiPiro Virginia Commonwealth University, University of Georgia, [email protected] See next page for additional authors Follow this and additional works at: http://scholarscompass.vcu.edu/pharmacy_dean_pubs Part of the Pharmacy and Pharmaceutical Sciences Commons This is a copy of an article published in Surgical Infections © 2004 copyright Mary Ann Liebert, Inc.; Surgical Infections is available online at: http://online.liebertpub.com. Downloaded from http://scholarscompass.vcu.edu/pharmacy_dean_pubs/13 This Article is brought to you for free and open access by the Office of the Dean at VCU Scholars Compass. It has been accepted for inclusion in Publications from the Office of the Dean by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Authors John A. Bailey, Katherine S. Virgo, Joseph T. DiPiro, Avery B. Nathens, Robert G. Sawyer, and John E. Mazuski This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/pharmacy_dean_pubs/13 SURGICAL INFECTIONS Volume 3, Number 4, 2002 © Mary Ann Liebert, Inc. Aminoglycosides for Intra-Abdominal Infection: Equal to the Challenge? JEFFREY A. BAILEY, 1 KATHERINE S. VIRGO, 1 JOSEPH T. D IPIRO,2 AVERY B. NATHENS, 3 ROBERT G. SAWYER, 4 and JOHN E.
    [Show full text]
  • APO-Roxithromycin Roxithromycin Consumer Medicine Information
    APO-Roxithromycin Roxithromycin Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet · acute pharyngitis (sore throat and Before you take it discomfort when swallowing) This leaflet answers some common · tonsillitis When you must not take it questions about roxithromycin. It · sinusitis does not contain all the available Do not take this medicine if you information. It does not take the · acute bronchitis (infection of the have an allergy to: bronchi causing coughing) place of talking to your doctor or · roxithromycin pharmacist. · worsening of chronic bronchitis · any other macrolide antibiotics All medicines have risks and · pneumonia (lung infection (e.g. azithromycin, clarithromycin benefits. Your doctor has weighed characterised by fever, malaise, or erythromycin) the risks of you using this medicine headache) · any of the ingredients listed at the against the benefits they expect it · skin and soft tissue infections end of this leaflet will have for you. · non gonococcal urethritis Some of the symptoms of an allergic Ask your doctor or pharmacist: · impetigo (bacterial infection reaction may include: · if there is anything you do not causing sores on the skin) · shortness of breath understand in this leaflet, · wheezing or difficulty breathing · if you are worried about taking How it works your medicine, or · swelling of the face, lips, tongue, Roxithromycin is an antibiotic that throat or other parts of the body · to obtain the most up-to-date belongs to a group of medicines · rash, itching or hives on the skin information. called macrolides. You can also download the most up These antibiotics work by killing or Do not take this medicine if you to date leaflet from stopping the growth of the bacteria have severe liver problems.
    [Show full text]
  • Synthesis of Netilmicin and Apramycin Derivatives for the Rt Eatment of Multidrug- Resistant Infectious Diseases Amr Sayed Motawi Sonousi Wayne State University
    Wayne State University Wayne State University Dissertations 1-1-2017 Synthesis Of Netilmicin And Apramycin Derivatives For The rT eatment Of Multidrug- Resistant Infectious Diseases Amr Sayed Motawi Sonousi Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Organic Chemistry Commons Recommended Citation Sonousi, Amr Sayed Motawi, "Synthesis Of Netilmicin And Apramycin Derivatives For The rT eatment Of Multidrug-Resistant Infectious Diseases" (2017). Wayne State University Dissertations. 1880. https://digitalcommons.wayne.edu/oa_dissertations/1880 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. SYNTHESIS OF NETILMICIN AND APRAMYCIN DERIVATIVES FOR THE TREATMENT OF MULTIDRUG-RESISTANT INFECTIOUS DISEASES by AMR SONOUSI DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2017 MAJOR: CHEMISTRY (Organic) Approved By: Advisor Date DEDICATION I dedicate my PhD work to my parents Sayed Sonousi and Hoda Fayed for nursing me with affection and love and for their dedicated partnership for success in my life. I also dedicate my work to my wife Tasnim Kandeel for her endless love and support for me throughout the process. ii ACKNOWLEDGEMENTS I would first like to express my utmost appreciation to my advisor, Professor David Crich, for his endless patience, brilliant guidance, continuous encouragement, and constant support during the past five years of my Ph.D. studies. His passion and dedication for science will always be my example to follow.
    [Show full text]
  • Danmap 2006.Pmd
    DANMAP 2006 DANMAP 2006 DANMAP 2006 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark Statens Serum Institut Danish Veterinary and Food Administration Danish Medicines Agency National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark Editors: Hanne-Dorthe Emborg Danish Zoonosis Centre National Food Institute, Technical University of Denmark Mørkhøj Bygade 19 Contents DK - 2860 Søborg Anette M. Hammerum National Center for Antimicrobials and Contributors to the 2006 Infection Control DANMAP Report 4 Statens Serum Institut Artillerivej 5 DK - 2300 Copenhagen Introduction 6 DANMAP board: National Food Institute, Acknowledgements 6 Technical University of Denmark: Ole E. Heuer Frank Aarestrup List of abbreviations 7 National Veterinary Institute, Tecnical University of Denmark: Sammendrag 9 Flemming Bager Danish Veterinary and Food Administration: Summary 12 Justin C. Ajufo Annette Cleveland Nielsen Statens Serum Institut: Demographic data 15 Dominique L. Monnet Niels Frimodt-Møller Anette M. Hammerum Antimicrobial consumption 17 Danish Medicines Agency: Consumption in animals 17 Jan Poulsen Consumption in humans 24 Layout: Susanne Carlsson Danish Zoonosis Centre Resistance in zoonotic bacteria 33 Printing: Schultz Grafisk A/S DANMAP 2006 - September 2007 Salmonella 33 ISSN 1600-2032 Campylobacter 43 Text and tables may be cited and reprinted only with reference to this report. Resistance in indicator bacteria 47 Reprints can be ordered from: Enterococci 47 National Food Institute Escherichia coli 58 Danish Zoonosis Centre Tecnical University of Denmark Mørkhøj Bygade 19 DK - 2860 Søborg Resistance in bacteria from Phone: +45 7234 - 7084 diagnostic submissions 65 Fax: +45 7234 - 7028 E.
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • The First Linezolid‑Resistant Enterococcus Faecium in India: High Level Resistance in a Patient with No Previous Antibiotic Exposure
    Published online: 2021-08-09 CASE REPORT The first linezolid‑resistant Enterococcus faecium in India: High level resistance in a patient with no previous antibiotic exposure Simit Kumar, Maitreyi Bandyoapdhyay, Mitali Chatterjee, Prabir Mukhopadhyay, Sumon Poddar, Parthajit Banerjee Department of Microbiology, R.G. Kar Medical College and Hospital, Kolkata, West Bengal, India Access this article online ABSTRACT Website: www.avicennajmed.com DOI: 0.4103/2231-0770.127416 Linezolid provides high rates of the clinical cure and microbiological success in complicated Quick Response Code: infections due to Enterococcus spp., including vancomycin‑resistant Enterococcus faecium. However, the emergence of resistance during linezolid treatment has been reported for clinical strains of Enterococcus, which is alarming given the fact that, this leaves the clinician with very few treatment options. We report the first case of linezolid resistantEnterococcus faecium from India, which was isolated from the blood culture of a hypoglycemic encephalopathy patient. There have been previous reports of linezolid resistant enterococci from different parts of the world, with minimum inhibitory concentration (MIC) ranging from 16 to 64 µg/mL and most of them were associated with vancomycin resistance but the isolate reported over here had an MIC of 1024 µg/mL and interestingly was sensitive to vancomycin. Key words: Enterococcus faecium, linezolid resistant, testing methods for detecting linezolid minimum inhibitory concentration INTRODUCTION isolates found to date. Previously reported patient factors that might pre‑dispose to the development of linezolid Linezolid, a member of the oxazolidinone class of antibiotics, resistance include indwelling intravascular devices, under exerts antibacterial activity by inhibiting the formation of dosage, immunosuppression after transplantation and the 70S initiation complex.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]
  • Swedres/Svarm 2017
    2017 SWEDRES|SVARM Consumption of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2017 A report on Swedish Antibiotic Utilisation and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Erika Olsson and Olov Aspevall, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden SE-171 82 Solna, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text and tables may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2017. Consumption of antibiotics and occur- rence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 18003 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2017 as a pdf in publicerat-material/ or at www.sva.se your mobile device, for reading and sharing. Download a free QR code reader in the App Store for Apple Layout: Dsign Grafisk Form, Helen Eriksson AB devices or in Google Play for Android, for example Quick Scan QR Code Reader (iPhone) or QR Droid Code Scanner Print: Taberg Media Group, Taberg 2018 (Android).
    [Show full text]
  • NORM Normgvet
    2O16 NORM NORM-VET Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway DESIGN, FORSIDE: IDA SKAAR IDA FORSIDE: DESIGN, – SVANEGODKJENT TRYKKSAK – 241 762 241 – TRYKKSAK SVANEGODKJENT – ISSN: 1502-2307 (print) / 1890-9965 (electronic) AS MEDIA LUNDBLAD 2016 NORM NORM-VET Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway ISSN: 1502-2307 (print) / 1890-9965 (electronic) Any use of data from NORM/NORM-VET 2016 should include specific reference to this report. Suggested citation: NORM/NORM-VET 2016. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø / Oslo 2017. ISSN:1502-2307 (print) / 1890-9965 (electronic). This report is available at www.vetinst.no and www.antibiotikaresistens.no 1 CONTENTS NORM / NORM-VET 2016 CONTRIBUTORS AND PARTICIPANTS Editors: Gunnar Skov Simonsen NORM, Univ. Hosp. North Norway Anne Margrete Urdahl NORM-VET, Norwegian Veterinary Institute Authors: Per Espen Akselsen Antibiotic usage in humans [email protected] KAS, Haukeland Univ. Hosp. Cecilie Torp Andersen Candida spp. [email protected] Oslo Univ. Hosp. Elisabeth Astrup MRSA in humans [email protected] Norw. Inst. of Pub. Health Hege Salvesen Blix Antibiotic usage in humans [email protected] Norw. Inst. of Pub. Health Dominique Caugant Meningococci [email protected] Norw. Inst. of Pub. Health Petter Elstrøm MRSA in humans [email protected] Norw. Inst. of Pub. Health Hege Enger MRSA in humans [email protected] St. Olav Univ. Hosp. Frode Width Gran MRSA in humans [email protected] St. Olav Univ. Hosp. Kari Grave Antibiotic usage in animals [email protected] Norw.
    [Show full text]
  • Prevalent Bacteria and Their Sensitivity and Resistance Pattern to Antibiotics: a Study in Dhaka Medical College Hospital
    PREVALENT BACTERIA AND THEIR SENSITIVITY AND RESISTANCE PATTERN TO ANTIBIOTICS: A STUDY IN DHAKA MEDICAL COLLEGE HOSPITAL. HOSSAIN MZ1, NAHER A2, HASAN P3, MOZAZFIA KT4, TASNIM H5, FERDUSH Z6, TOWHID KMS7, IMRAN MAA8 Abstract Background and rationale: Antibiotic resistance is a global problem. Many factors are complexly related to the issue in multiple dimensions. Bangladesh is right in the middle of this great calamity, and is seeing the rise in resistant strains of several bacteria. Very sadly, the prevalent malpractice of abusing antibiotics in Bangladesh contributes to add complexity to the danger which may prove to be possibly the greatest threat humans have ever faced. There is much scarcity of medical literature in Bangladesh, on the antibiotic sensitivity pattern and prevalent microorganisms. Moreover, antibiotic sensitivity pattern changes over time and place. Again, most of the studies done in Bangladesh, concentrate on a single disease, pathogen, or specimen. This study attempts to see the prevalent microorganisms and the antibiotic sensitivity pattern in multiple types of specimens collected from Dhaka Medical College Hospital. This study also attempts to establish a way of presentation of the relevant findings which can be used in future to ensure easy comparability and contrasting of findings. Methods: The specimens were collected from the adult patients (age >12 years) admitted in the Internal Medicine ward of Dhaka Medical College Hospital, Dhaka, over a period of 6 months. The sampling technique was consecutive sampling method. Specimens which were culture positive, were only included in the study for analysis. Multiple specimens were taken. Results: S. aureus was 100% sensitive to amikacin, moxifloxacin, imipenem, meropenem, piperacillin+tazobactum combination, vancomycin, doxycycline, tetracycline, tigecycline, nitrofurantoin, azactum, linezolid and 100% resistant to cefixime.
    [Show full text]
  • Retrospective Study of Outcome in Patients Treated for Staphylococcus
    ORIGINAL ARTICLE Retrospective study of outcome in patients treated for Staphy 1ococcus aureus b ac teremia Pauline E. Gosdenl, Barnaby C. Reeves2,]ames R. S. Osborne3, Andrew Turner' and Michael R. Millarl 'Department of mcrobiology, 2Research and Development Support Unit, and 3Department of Pathology, University of Bristol, Bristol Royal Infirmary, United Bristol Healthcare Trust, Bristol, UK Objective: To investigate whether a change in current treatment practice for Staphylococcus aureus bacteremia from flucloxacillin and aminoglycoside to flucloxacillin and fusidic acid was associated with any changes in outcome. Methods: A retrospective analysis was carried out of 316 episodes of S. aureus bacteremia diagnosed and treated in a tertiary hospital complex between 1983 and 1993. Outcomes considered were (1) death related to the infection and (2) relapse following cessation of antibiotic therapy. Results: Mortality related to infection, which occurred in 24% of patients, was unrelated to treatment with the combination of flucloxacillin and fusidic acid; however, increasing age was a significant risk factor (OR per decade = 1.35, 95% CI = 1.1&1.55), and increasing duration of treatment (OR per week of treatment = 0.63,95% CI = 0.52-0.77), use of flucloxacillin (OR= 0.30,95% CI = 0.14-0.64). presence of an intravascular device (OR= 0.39,95% CI = 0.20-0.78) and presence of a skin lesion (OR = 0.51, 95% CI = 0.26-0.99) were significant protective factors. The only factor significantly related to relapse, which occurred in 11% of patients, was treatment with the combination of flucloxacillin and fusidic acid (OR = 0.32, 95% CI = 0.12-0.85).
    [Show full text]